Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BKM120 with Cisplatin and Etoposide in Advanced Solid Tumors/SCLC
NCT02194049Phase 1Completed
- Sponsor
- University of California, Davis
- Start
- Jul 2014
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of buparlisib in solid tumor and small cell lung cancer (SCLC), sponsored by University of California, Davis. Primary endpoint: Incidence of adverse events. Started Jul 2014; status: completed.
02
Drugs
buparlisib
03
Conditions
solid tumorsmall cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT02194049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02194049.